Be Ready To Distribute A COVID-19 Vaccine In Two Months, CDC Tells All States

The United States Centers for Disease Control and Prevention notified public health authorities in all 50 states and five large cities to begin preparations to distribute two unidentified vaccines in late October or early November, the New York Times reported Wednesday.

What Happened: The two vaccines which the CDC is calling — Vaccine A and Vaccine B — will be distributed to health care workers and other persons falling in high-risk groups, according to the Times.

The agency has reportedly spelled out technical specifications for both vaccines including requirements for their shipping, mixing, storage and administration.

The specifications indicate that these vaccines are likely ones being made by Pfizer Inc PFE and Moderna Inc MRNA, which are in advanced clinical trials, as per the Times.

The scenarios reportedly assume that the two vaccines will be deemed safe and effective enough to receive an emergency authorization from the Food and Drug Administration by the end of October.

Why It Matters: The CDC guidelines, in the form of three documents, were sent out to officials in all states and five cities on Aug. 27— the same day President Donald Trump announced at the Republican National Convention that a vaccine may be available before the end of 2020, the Times noted.

Vaccine A, which may be Pfizer’s product is likely to have 2 million doses ready by October and Vaccine B, the one most likely made by Moderna, would have one million doses ready by that period, according to the documents. 

The documents state that tens of millions of doses would be ready by the end of the year.

Johnson & Johnson JNJ, Pfizer and its partner BioNTech SE BNTX, AstraZeneca Plc AZN, and Sanofi SA SNY along with GlaxoSmithKline plc GSK have deals in place to supply vaccines to the government.

Price Action: Pfizer shares closed 0.84% higher at $37.20 on Wednesday and gained 0.30% in the after-hours session. On the same day Moderna shares closed nearly 2.2% higher at $64.72 and rose almost 0.3% in the after-hours session.

Posted In: CDCCoronavirusCovid-19The New York TimesU.S. Centers for Disease Control and PreventionVaccinesBiotechGovernmentNewsRegulationsHealth CareFDALegalMediaGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.